Dr. Jonathan (Josh) Bloom, ACSH’s Director of Chemical and Pharmaceutical Science, earned his Ph.D. in organic chemistry at the University of Virginia, followed by postdoctoral training at the University of Pennsylvania. His first career was in drug discovery research, mostly at Wyeth. During this time he participated in research in a number of therapeutic areas, including diabetes and obesity, new antibiotics, HIV/AIDS, and hepatitis C. His group discovered the novel antibiotic Tygacil®, which was approved by the FDA for use against resistant bacterial infections in 2005. He is the author of 25 patents, and 35 academic papers, including a chapter on new therapies for hepatitis C in Burger’s Medicinal Chemistry, Drug Discovery, and Development, 7th Edition (Wiley, 2010). Dr. Bloom joined the American Council on Science and Health in 2010 as Director of Chemical and Pharmaceutical Sciences.
The articles featured are:
DEA Chasing Its Tail Again: This Time, It’s ‘Synthetic Cannabinoids’
DEA Chasing Its Tail Again: This Time, It’s ‘Synthetic Cannabinoids’
Tylenol Plus Advil Combo: Innovation Or Exploitation?
Tylenol Plus Advil Combo: Innovation Or Exploitation?
